Osaka, Japan, and Fort Worth, Texas, September 17, 2020 — Santen Pharmaceutical Co., Ltd. (hereinafter “Santen”) and Eyevance Holdings LLC announced that Santen Holdings U.S.

Eyevance Pharmaceuticals Launches ZERVIATE™ in the United States ZERVIATE™ (cetirizine ophthalmic solution) 0.24% is the first novel prescription-only treatment for allergic conjunctivitis in 10 years

Eyevance Pharmaceuticals launches TOBRADEX® ST in the United States Product targets inflammatory eye conditions, with risk of infection such as blepharitis and meibomian gland dysfunction

Eyevance Pharmaceuticals Appoints Julie Speed as Chief Commercial Officer Ms. Speed brings over 21 years of successful ophthalmic experience Eyevance poised to have three additional

Eyevance Pharmaceuticals Acquires TOBRADEX® ST and NATACYN® Acquisition bolsters Eyevance’s position as an emerging leader in treating anterior segment and ocular surface conditions Company executes

Eyevance Pharmaceuticals Executes Strategic Transaction Acquires exclusive rights to commercialize FLAREX® in the United States October 24, 2018 – Fort Worth, Texas – Eyevance Pharmaceuticals,

Eyevance Pharmaceuticals Acquires Worldwide Rights to NEXAGON® October 2, 2018 – Fort Worth, Texas – Eyevance Pharmaceuticals, a Fort Worth-based pharmaceutical company committed to developing

Eyevance Pharmaceuticals Acquires FRESHKOTE® Lubricant Eye Drop Family of Products from Focus Laboratories Immediate introduction of new FRESHKOTE® Preservative Free (PF), in a multi-dose bottle

Eyevance Pharmaceuticals LLC™, a Recently Established Ophthalmic Company, Enters into an Exclusive Licensing Agreement for ZERVIATE™ in the United States, the First Topical, Ocular Formulation